Cue Biopharma, Inc. (CUE)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
CRITICAL DILUTION RISKDilution score: 89/100 (CRITICAL), 5.3 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 9.19% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
- Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
- An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
- Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
- Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
- Cue Biopharma Announces $50.0 Million Private Placement
- Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
- Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Cue Biopharma, Inc..
Full CUE Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.